Concepedia

Publication | Open Access

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

DOIFull Paper Access

151

Citations

19

References

2021

Year

Alessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, Vincent Cottin, Franco Franceschini, Stefano Del Giacco, Franco Schiavon, Thomas Neumann, Giuseppe Lopalco, Pavel Novikov,
Arthritis & Rheumatology

Abstract

Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses should be compared in the setting of a controlled trial.

References

YearCitations

Page 1